Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Laura A. Michaelis"'
Publikováno v:
Frontiers in Communication, Vol 6 (2021)
Denominal verbs are produced by a syntactic category shift, conversion, in which the word’s inflectional and combinatory potential change while its internal composition does not (Valera, 2015: 322). Perhaps no language owes as many of its verbs to
Externí odkaz:
https://doaj.org/article/ed9f8b11223c45608a3ebb5375d05f92
Autor:
Chandrasekar Muthiah, Qinghua Lian, Samantha Benz, Aniko Szabo, Karin Hoffmeister, Juliana Perez Botero, Laura C. Michaelis
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/01158b95f88e403e96815539bf0c516a
Autor:
Philip C. Berce, PharmD, Leah Cardwell, MD, Amber N. Essenmacher, PA-C, Laura C. Michaelis, MD, Karolyn A. Wanat, MD
Publikováno v:
JAAD Case Reports, Vol 22, Iss , Pp 110-113 (2022)
Externí odkaz:
https://doaj.org/article/59f0c1c44e214b64b1060ffab2feeef7
Autor:
Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay R. Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A. Bejan, Merrida Childress, Ingrid Anderson, Kyle Rawling, Rhea M. Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing V. Dudley, P. Brent Ferrell, Michael Byrne, Stephen A. Strickland, Gregory D. Ayers, Bennett A. Landman, Emily F. Mason, Ruben A. Mesa, Jeanne M. Palmer, Laura C. Michaelis, Michael R. Savona
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a850abe032c828055182ec36c5ab409
https://doi.org/10.1158/1078-0432.ccr-22-3192
https://doi.org/10.1158/1078-0432.ccr-22-3192
Autor:
Yaping Chang, Gordon H Guyatt, Trevor Teich, Jamie L Dawdy, Shaneela Shahid, Jessica K Altman, Richard M Stone, Mikkael A Sekeres, Sudipto Mukherjee, Thomas W LeBlanc, Gregory A Abel, Christopher S Hourigan, Mark R Litzow, Laura C Michaelis, Shabbir M H Alibhai, Pinkal Desai, Rena Buckstein, Janet MacEachern, Romina Brignardello-Petersen
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0249087 (2021)
To compare the effectiveness and safety of intensive antileukemic therapy to less-intensive therapy in older adults with acute myeloid leukemia (AML) and intermediate or adverse cytogenetics, we searched the literature in Medline, Embase, and CENTRAL
Externí odkaz:
https://doaj.org/article/cb2e4ee8a8d8462e86a8fcc1f73eb6e0
Autor:
Laura A. Michaelis
Publikováno v:
Cognitive Semantics. 8:383-408
Coercion is an inferential strategy used to resolve conflict between an operator and its argument. Such conflicts are resolved in favor of the semantic requirements of the operator (Talmy, 2000). Jackendoff (1997) and De Swart (1998), among others, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c90bdbc8d8465612f5cf3286533a6c84
https://doi.org/10.1163/23526416-bja10036
https://doi.org/10.1163/23526416-bja10036
Autor:
Laura A. Michaelis, Daniel Altshuler
We examine the constellation of factors – lexical, aspectual, temporal and conversational – that give rise to evidential implications from assertions. We target intensional and inferential meanings associated with a certain class of present-tense
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5222f0bf7927a1a353248b3f9cceb7ee
https://ora.ox.ac.uk/objects/uuid:0c42205f-2617-4bbb-9a0d-384657abc683
https://ora.ox.ac.uk/objects/uuid:0c42205f-2617-4bbb-9a0d-384657abc683
Autor:
Michael R. Savona, Laura C. Michaelis, Jeanne M. Palmer, Ruben A. Mesa, Emily F. Mason, Bennett A. Landman, Gregory D. Ayers, Stephen A. Strickland, Michael Byrne, P. Brent Ferrell, Channing V. Dudley, Aunshka Collins, Laura Dugger, Rebekah Caza, Ashley Moncrief, Rhea M. Simons, Kyle Rawling, Ingrid Anderson, Merrida Childress, Cosmin A. Bejan, Yucheng Tang, Hyeonsoo Moon, Yuankai Huo, Run Fan, Sheau-Chiann Chen, Tess Stopczynski, Sanjay R. Mohan, Brandon McMahon, Matthew T. Villaume, Ashwin Kishtagari, Tamara K. Moyo
Supplemental Tables S1-S9 Supplemental Figures S1-S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00824c6ff87fc381e622ce00f6089201
https://doi.org/10.1158/1078-0432.22787600.v1
https://doi.org/10.1158/1078-0432.22787600.v1
Autor:
Michael R. Savona, Laura C. Michaelis, Jeanne M. Palmer, Ruben A. Mesa, Emily F. Mason, Bennett A. Landman, Gregory D. Ayers, Stephen A. Strickland, Michael Byrne, P. Brent Ferrell, Channing V. Dudley, Aunshka Collins, Laura Dugger, Rebekah Caza, Ashley Moncrief, Rhea M. Simons, Kyle Rawling, Ingrid Anderson, Merrida Childress, Cosmin A. Bejan, Yucheng Tang, Hyeonsoo Moon, Yuankai Huo, Run Fan, Sheau-Chiann Chen, Tess Stopczynski, Sanjay R. Mohan, Brandon McMahon, Matthew T. Villaume, Ashwin Kishtagari, Tamara K. Moyo
Purpose:Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66f4bf7c7d922639cc2f4c32c3e57a35
https://doi.org/10.1158/1078-0432.c.6637754.v1
https://doi.org/10.1158/1078-0432.c.6637754.v1
Autor:
Jordan R. Hanrahan, Leroy J. Seymour, Anna Beckius, Donna Welter, Mandy Kastner, Valarie Ehrlich, Kristine Broge-Reynen, Mary Rodgers, Laura C. Michaelis, Lyndsey Runaas, Ehab L. Atallah, Sameem Abedin, Guru Subramanian Guru Murthy, Ravi Kishore Narra, Mary Fournogerakis, Jessica Schmitz, Andrea Viitala, Elizabeth Larsen, Amber Essenmacher, Gina George, Kim Johnston, Karen Sue Carlson, Nicole Held
Publikováno v:
Blood. 140:5083-5085
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a9883dcca2af3487cdfc99e4ae803d3
https://doi.org/10.1182/blood-2022-159809
https://doi.org/10.1182/blood-2022-159809